Search clinical trials for: BMS-986301

Total 3174 results

Bristol-Myers Squibb

Completed

Single Dose Study of BMS-820836

Depression

Canada
Bristol-Myers Squibb

Completed

A Phase I Study to Assess the Electrophysiologic Effects of BMS-394136 on the Atrium and Ventricle in Patients With Dual-Chamber Pacemakers or Defibrillators

Heart Diseases

United States
Bristol-Myers Squibb

Recruiting

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread (CheckMate-67T)

Clear Cell Renal Cell Carcinoma

Russian Federation, New Zealand, United States, Finland, France, Ireland, Italy, Turkey, Poland, Argentina, Brazil, Chile, Czechia, Mexico, Portugal, Romania, Spain
The Netherlands Cancer Institute
Bristol-Myers Squibb

Completed

Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy (NABUCCO)

Urothelial Carcinoma

Netherlands
Bristol-Myers Squibb

Completed

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) (CheckMate 848)

Pan Tumor

United States, Puerto Rico, Italy, Argentina, Australia, Belgium, Canada, Chile, Denmark, France, Germany, Netherlands, Poland, Romania, Singapore, Spain, United Kingdom
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies (CheckMate 908)

Various Advanced Cancer

United States, Australia, Brazil, Canada, France, Germany, Hong Kong, Israel, Netherlands, Norway, Poland, Russian Federation, Spain, Sweden, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Completed

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies (MDX1106-03)

Renal Cell Carcinoma | Metastatic Melanoma | Non-small Cell Lung Cancer | Metastatic Castration-resistant Prostrate Cancer

United States
Bristol-Myers Squibb

Withdrawn

A Safety Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Non-small Cell Lung Cancer (CheckMate 955)

Non-Small Cell Lung Cancer

Argentina, Peru, Germany, United States, Canada
Bristol-Myers Squibb

Completed

Japanese Study of BMS-901608 (Elotuzumab) in Combination With Lenalidomide and Low Dose Dexamethasone

Multiple Myeloma

Japan
Bristol-Myers Squibb

Completed

Phase III China GT 1b Interferon (IFN) Intolerant Prev Exclude Dual

Hepatitis C

China, Korea, Republic of, Taiwan
Bristol-Myers Squibb

Completed

Three-year Follow-up Study of Subjects Who Participated in a Previous Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Chronic Hepatitis C Clinical Trial

Hepatitis C

United States, Australia, France, Japan, Spain, Sweden, Canada, Germany, Mexico, Denmark, Italy, Korea, Republic of, Taiwan, Argentina, Brazil, Ireland, Poland, Puerto Rico, United Kingdom
Bristol-Myers Squibb
Yale University

Completed

An Exploratory Study of the Effects of Nivolumab Combined With Ipilimumab in Patients With Treatment-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (CheckMate 592)

Non-Small Cell Lung Cancer

Belgium, Italy, United States, France, Germany, Netherlands, Spain, Romania
Hackensack Meridian Health

Terminated

Single Agent and Combined Inhibition After Allogeneic Stem Cell Transplant (CPIT-002)

Acute Myeloid Leukemia and Myelodysplastic Syndrome

United States
Bristol-Myers Squibb

Terminated

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer

Cancer

United States
Boston Scientific Corporation

Completed

PROPPER Prospective Registry of Outcomes With Penile Prosthesis (PROPPER)

Erectile Dysfunction | Impotence

United States, Canada
Bristol-Myers Squibb

Completed

A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer

Hepatocellular Carcinoma (HCC)

France, Korea, Republic of, Taiwan, United States, Singapore, Philippines, Malaysia, Hong Kong
Bristol-Myers Squibb

Completed

Safety Study of BMS-823778 in Subjects With Hypercholesterolemia

Dyslipidemia

Canada, United States, Australia
Bristol-Myers Squibb

Completed

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

Chronic Hepatitis C

United States, Argentina
Bristol-Myers Squibb

Terminated

A Safety Study of BMS-852927 in Subjects With Hypercholesterolemia

Hypercholesterolemia

Germany, Canada
Leonardo Bolognese, MD

Terminated

A Comparison Between Paclitaxel-eluting Balloon in Combination With BMS Implantation vs Conventional Balloon and DES Implantation (ELICOPTER)

Myocardial Ischemia

Italy
Georgetown University
Bristol-Myers Squibb; M.D. Anderson Cancer Center; University of Colorado, Denver and other collaborators

Terminated

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

Mucosal Melanoma | Acral Lentiginous Melanoma

United States
Melanoma Institute Australia
Bristol-Myers Squibb; Melanoma and Skin Cancer Trials Limited

Active, not recruiting

Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases (ABC)

Melanoma | Brain Metastases

Australia
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb

Completed

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

Peripheral T Cell Lymphoma

United States
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India (CheckMate 7C9)

Kidney Neoplasms

India
Bristol-Myers Squibb

Completed

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

Melanoma

United States
Bristol-Myers Squibb

Completed

A Phase 3 Study in Combination With BMS-790052 and BMS-650032 in Japanese Hepatitis C Virus (HCV) Patients

Hepatitis C

Japan
Bristol-Myers Squibb

Completed

Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-933043 in Healthy Subjects

Healthy Adult Normals

United States
Bristol-Myers Squibb

Completed

Single Ascending Dose Study of BMS-820132 in Patients With Type 2 Diabetes

Diabetes Mellitus, Non-Insulin-Dependent

United States
R-Pharm

Completed

Clinical Study of Ixabepilone (BMS-247550) by Every-3-week Dosing Regimen in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and Who Are Taxane Resistant

Metastatic Breast Cancer
The Netherlands Cancer Institute

Completed

ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma (IMCISION)

Head and Neck Neoplasms | Immunotherapy

Netherlands
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)

Melanoma

Belgium, Brazil, United States, Canada, Spain, Greece, France, United Kingdom, Australia, Italy, Austria, Switzerland, Germany, Israel, Russian Federation, Romania, Czechia, Poland, New Zealand
Bristol-Myers Squibb

Terminated

Study to Evaluate the Safety, Tolerability, PK, and PD of BMS-986090 in Healthy Subjects

Healthy Adult Volunteers

United States
Bristol-Myers Squibb

Withdrawn

Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma (PD-L1)

Stage III or IV Melanoma
Bristol-Myers Squibb

Completed

A Study of Nivolumab in Combination With Ipilimumab in Chinese Participants With Previously Treated Advanced or Recurrent Solid Tumors

Solid Tumor

China
Bristol-Myers Squibb

Completed

A Study to Evaluate the Safety of Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Cancer (CHECKMATE 920)

Renal Cell Carcinoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Withdrawn

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

Resectable Biliary Tract Cancer
National Cancer Institute (NCI)

Terminated

Ixabepilone to Treat Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Carcinoma | Cervical Carcinoma, Non-SquamousType

United States
Bristol-Myers Squibb

Completed

An Investigational Study of Immunotherapy Combinations With Chemotherapy in Patients With Gastric or Gastroesophageal Junction (GEJ) Cancers

Gastric Cancer | Esophagogastric Junction | Cancer of the Stomach

United States, Germany, Italy, Argentina, Australia, Belgium, France, Poland, Puerto Rico, Spain, Czechia, Austria, Canada, United Kingdom, Chile, Norway, Singapore
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Immune Response of BMS-936559 in HIV-Infected People Taking Combination Antiretroviral Therapy

HIV Infections

United States
Bristol-Myers Squibb

Completed

A Study to Determine the Pharmacokinetic Profile of BMS-986165 Tablets

Lupus

United Kingdom
Bristol-Myers Squibb

Terminated

A Study Evaluating the Drug Levels of Iplimumab Given Under the Skin Alone and in Combination With Nivolumab in Multiple Tumor Types (CheckMate 76U)

Tumor

Italy, United States, New Zealand
Bristol-Myers Squibb
Medarex; Ono Pharma USA Inc

Completed

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

Malignant Melanoma

United States
Bristol-Myers Squibb

Completed

A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)

Healthy Participants

United States
Mansoura University

Unknown

Effect of Gastric Balloon in Morbid Obesity: Prospective Study

Morbid Obesity

Egypt
JIANYANG WANG
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting

The Effect of Prophylactic TPO Combined With BMS-IMRT to Esophageal Cancer Patients

Esophageal Cancer | Thrombocytopenia | Concurrent Chemoradiotherapy | Intensity-modulated Radiation Therapy

China
Bristol-Myers Squibb

Completed

A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435

Healthy Volunteers

United States
National Cancer Institute (NCI)
NRG Oncology

Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Clear Cell Adenocarcinoma | Fallopian Tube Clear Cell Adenocarcinoma

United States
Samsung Medical Center

Completed

The Compliance of DAPT and Statins on Clinical Outcomes in Percutaneous Coronary Intervention Patients (CPPCI)

Adherence, Medication | Percutaneous Coronary Intervention | Compliance, Medication | Platelet Aggregation Inhibitors | Hydroxymethylglutaryl-coa Reductase Inhibitors | Persistence, Medication

Korea, Republic of
R-Pharm

Completed

Novel Epothilone (BMS-247550) in Patients With Metastatic Breast Cancer (MBC)

Breast Cancer | Metastases

United States, Netherlands, Argentina, Canada, South Africa, Mexico, Norway, Sweden, France, Germany
National Cancer Institute (NCI)

Completed

BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy

Recurrent Prostate Cancer | Bone Metastases | Hormone-resistant Prostate Cancer | Adenocarcinoma of the Prostate | Stage IV Prostate Cancer

United States

Search clinical trials for: BMS-986301

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations